Clinical Trial Update: A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating belantamab mafodotin in combination with daratumumab, lenalidomide, and dexamethasone for newly diagnosed, transplant-inel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Belantamab Mafodotin (belantamab mafodotin)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Hellenic Society of Hematology | Conditions: Multiple Myeloma, Neoplasms | Phase 1, Phase 2 | Status: UNKNOWN